The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats

British Journal of Pharmacology
S OkuyamaK Tomisawa

Abstract

1. The atypical antipsychotic profile of (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl] thiazole (NRA0045), a potent dopamine D4 and 5-hydroxytryptamine (5-HT)2A receptor antagonist, was examined in rats. 2. Spontaneous locomotor activity was decreased dose-dependently with i.p. administration of clozapine (ED50 3.7 mg kg-1), haloperidol (ED50 0.1 mg kg-1) and chlorpromazine (ED50 0.9 mg kg-1), whereas inhibition of this type of behaviour induced by i.p. administration of NRA0045, at doses up to 10 mg kg-1, did not exceed 50%. 3. Locomotor hyperactivity induced by methamphetamine (MAP, 2 mg kg-1, i.p.) in rats (a model of antipsychotic activity) was dose-dependently antagonized by NRA0045 (ED50 0.4 mg kg-1, i.p., and 0.3 mg kg-1, p.o., respectively), clozapine (ED50 0.3 mg kg-1, i.p. and 0.8 mg kg-1, p.o., respectively), haloperidol (ED50 0.02 mg kg-1, i.p. and 0.1 mg kg-1, p.o., respectively), chlorpromazine (ED50 0.3 mg kg-1, i.p. and 3.3 mg kg-1, p.o., respectively). In contrast, the MAP (3 mg kg-1, i.v.)-induced stereotyped behaviour in rats (a model of extrapyramidal symptoms) was not affected by NRA0045 or clozapine, at the highest dose given (30 mg kg-1, i.p.). Haloperidol (ED50 ...Continue Reading

References

Mar 1, 1992·Trends in Pharmacological Sciences·G P Reynolds
Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jan 1, 1990·Modern Problems of Pharmacopsychiatry·P BoyerA J Puech
Aug 1, 1988·Trends in Neurosciences·D R Weinberger
Jan 1, 1989·Psychopharmacology·D E Casey
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1980·Annual Review of Neuroscience·R J Baldessarini, D Tarsy
Apr 1, 1981·The American Journal of Psychiatry·S H Snyder
Apr 1, 1981·Pharmacology, Biochemistry, and Behavior·H WatanabeN Ogawa
Jan 1, 1981·Psychoneuroendocrinology·H Y MeltzerV S Fang
Aug 1, 1995·Journal of Clinical Psychopharmacology·U D McConn, G A Ricaurte
Feb 6, 1995·European Journal of Pharmacology·J F LiégeoisJ Delarge
Jan 1, 1995·Life Sciences·C J SchmidtM G Palfreyman
Jan 1, 1993·Psychopharmacology·J M GoldsteinJ B Malick
Jul 1, 1994·Trends in Pharmacological Sciences·P Seeman, H H Van Tol
Jan 1, 1994·Life Sciences·S OgawaS Otomo
May 10, 1996·Journal of Medicinal Chemistry·I BoyfieldG Stemp
Jan 1, 1996·European Psychiatry : the Journal of the Association of European Psychiatrists·T Lewander

❮ Previous
Next ❯

Citations

Jul 6, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Kathleen M GrantRick A Bevins
Oct 18, 2000·European Journal of Pharmacology·J N OakH H Van Tol
Jul 5, 2001·European Journal of Pharmacology·N KawashimaS Okuyama
Aug 28, 1998·European Journal of Pharmacology·J M WilsonH H Van Tol
Sep 16, 1998·Current Opinion in Chemical Biology·W S FaraciA Fliri
Feb 24, 2001·Fundamental & Clinical Pharmacology·S K Kulkarni, I Ninan
Jan 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Marie NilssonMaria L Carlsson
Dec 4, 2003·CNS Drug Reviews·Shiho HirotaShigeru Okuyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.